NEW YORK (GenomeWeb News) – Compugen today posted a $2.4 million profit for the second quarter due entirely to the sale of $3.6 million worth of shares that it held in Evogene.

The Tel Aviv, Israel-based firm reported total revenues of $225,000 for the three-month period ended June 30, compared to revenues of $40,000 for the second quarter of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."